1. Introduction {#s0005}
===============

Fatigue affects approximately half of all Parkinson\'s disease (PD) patients and is reported by one-third to be their single most disabling symptom ([@bb0160]). Fatigue in PD is also associated with diminished activity levels, quality of life, and physical function ([@bb0020]; [@bb0115]; [@bb0230]). Despite the undeniable impact of fatigue on persons living with PD, there has been relatively little study of its etiology and currently available treatments are minimally effective. Studies to date generally do not find significant associations between disease duration, disease stage, or motor symptoms with fatigue suggesting the involvement of nonmotor networks ([@bb0165]). Indeed, two prior functional imaging studies on PD-related fatigue suggested potential involvement of prefrontal cortex using SPECT perfusion ([@bb0010]) and serotonergic dysfunction in ventral striatum and thalamus and dopaminergic dysfunction in the caudate and insula using PET ligands ([@bb0270]). Regarding other potential secondary causes of fatigue in PD, fatigue is often associated with depression ([@bb0160]). However, depression and fatigue frequently exist independently and fatigue may persist following successful treatment of depression ([@bb0025]). Fatigue in PD is also inconsistently associated with sleep disorders and sleep quality and is dissociable from daytime somnolence ([@bb0375]; [@bb0370]; [@bb0330]).

Fatigue is common in many diseases and complaints may be driven by dysfunction in the peripheral nervous system (e.g. myasthenia gravis), CNS (e.g. multiple sclerosis), or other organ systems (e.g. heart failure) ([@bb0225]). Although this may seem to support the claim that fatigue is a nonspecific symptom, there are important differences in the phenomenology of fatigue in these diverse disorders and treatments targeted to the specific pathophysiological mechanism (e.g. anemia in cancer fatigue) are more effective than generic treatments (e.g. stimulants) ([@bb0260]). Regarding CNS causes of fatigue, Chaudhuri and Behan proposed a neuroanatomic model in which disruption of cortical-subcortical loops important for internal drive (ventral striatum, anterior cingulate cortex, thalamus) causes fatigue by altering one\'s ability to maintain consistent effort ([@bb0060], [@bb0065]). Lesion analysis in both stroke and multiple sclerosis support this model and argue that fatigue is indeed due to focal network dysfunctions and not global factors ([@bb0280]). While the high prevalence of fatigue in PD has been used to support this model (particularly the contributions of basal ganglia dysfunction to fatigue) it has not been directly tested in PD and does not address why approximately half of PD patients do not report significant fatigue.

As PD is associated with structural changes in cortical, subcortical, and white matter structures, we hypothesized that morphometric variability may be used to improve our understanding of the pathogenesis of fatigue as has been done with other nonmotor symptoms ([@bb0045]; [@bb0240]; [@bb0085]; [@bb0180]; [@bb0205]; [@bb0280]; [@bb0350]; [@bb0275]). Thus, our objectives in the current study were to utilize MR-morphometry and diffusion tensor imaging to identify cortical, subcortical, and white matter changes associated with fatigue in PD while controlling for potential confounds (e.g. sleep and depression) with the goal of improving our understanding of the pathogenesis of PD-related fatigue. We specifically hypothesized PD-related fatigue would be associated with anterior cingulate cortex, striatum, and insula volume. To address the question of whether fatigue in PD is primarily related to PD pathology or more generic factors related to aging, we also examined structural correlates of fatigue in healthy older adults.

2. Methods {#s0010}
==========

2.1. Participants {#s0015}
-----------------

This study was approved by the Institutional Review Board of the University of Florida, required individual consent form signature, and followed the Declaration of Helsinki. Recruitment involved a combination of: 1) brochure mailings to individuals identified through a research database within the University of Florida Center for Neurorestoration and Movement Disorder Center; 2) University of Florida Center for Neurorestoration and Movement Disorder Center direct neurology referrals; 3) advertisement at different PD support symposiums. All individuals were screened via telephone or in person and then completed a baseline cognitive testing to ensure they met cognitive screening criteria.

All participants had to be right-handed and speak fluent English. Individuals with PD were diagnosed by a movement disorder fellowship trained neurologist, met criteria outlined by the United Kingdom Parkinson\'s Disease Society Brain Bank Clinical Diagnostic Criteria ([@bb0210]), and had a Hoehn and Yahr scale ([@bb0200]) ranging from 1 to 3. All participants were tested while on-medication. Medical exclusions included having any underlying medical disease likely to limit lifespan or cause fatigue independent of PD: cancer requiring treatment in past five years (exception: non-melanoma skin cancer), serious infectious diseases (e.g., self-reported HIV), myocardial infarction or cerebrovascular accident in the last six months, congestive heart failure, chronic hepatitis, history of organ transplantation, seizure disorders, head trauma resulting in intensive care, or any other chronic medical condition likely to limit lifespan. Surgical exclusion included having undergone Deep Brain Stimulation Surgery. Neurodegenerative exclusions included evidence of secondary or atypical Parkinsonism as suggested by the presence of any of the following: 1) history of major stroke(s) associated with cognitive sequelae; 2) exposure to toxins or neuroleptics; 3) history of encephalitis; 4) neurological signs of upper motor neuron disease, cerebellar involvement, supranuclear palsy, or significant orthostatic hypertension. Patients were excluded if they presented with signs of a dementia as indicated by the neurological/ neuropsychological assessment, DSM-IV criteria, and Mattis Dementia Rating Scale corrected scale score \< 8 (please see [@bb0275] for full details of neuropsychological testing). Psychiatric exclusions included having a major psychiatric disorder as assessed by the psychiatric and neurological team with the Structured Clinical Interview for DSM-IV. Per patient record, those with histories of major depression were excluded. We did not exclude patients reporting mild depression or anxiety for many PD patients report such symptoms. Conditions or behaviors likely to affect cognitive testing included claustrophobia, non-medical bodily metal, pace-maker device, less than five years of normal education, inability to read or write, and self-reported hearing difficulty that interferes with standardized test administration. Data from select participants have been published elsewhere ([@bb0290]; [@bb0350]; [@bb0275]; [@bb0355]; [@bb0080]).

2.2. Fatigue severity {#s0020}
---------------------

Fatigue severity was measured using the Fatigue Severity Scale which is widely used, validated, and recommended for use in PD, including by the Movement Disorders Society Fatigue Task Force ([@bb0250]; [@bb0185]; [@bb0170]). The Fatigue Severity Scale is a 9-item questionnaire that asks patients to rate the severity and impact of fatigue on various aspects of daily life on a 1 to 7 scale (strongly disagree to strongly agree). We used the suggested cut-off point of 4 (9-item average) to identify individuals with clinically significant (moderate to severe) fatigue ([@bb0250]).

2.3. Sleep and depression {#s0025}
-------------------------

To control for the potentially confounding effects of sleep and depression we quantified sleep duration based on self-reported average number of hours of sleep per night. Data were acquired from a routine health screening completed as part of the parent investigation and within 24 h of the brain MRI. Depressive symptoms were measured using the total score from the BDI-II ([@bb0040]).

2.4. Parkinson\'s disease motor severity and levodopa equivalency dose {#s0030}
----------------------------------------------------------------------

PD motor severity on medication was quantified using part III of the Unified Parkinson Disease Rating Scale (S [@bb0120]) and then scored by trained and reliable raters. A database containing all participants\' medication and vitamins was recorded and reviewed by two separate raters. Medication containing L-dopa was converted to a common metric (Levodopa Equivalency Dose) ([@bb0360]) in which the drugs are compared in relation to the immediate release L-dopa dose (400 mg of the immediate release L-dopa dose is equivalent to 400 mg Levodopa Equivalency Dose).

2.5. MRI data acquisition {#s0035}
-------------------------

Neuroimaging data were prospectively acquired with a Siemens 3 T Verio scanner using an 8-channel head coil. For gray and white matter analyses we acquired two T1-weighted scans (176 contiguous slices, 1 mm^3^ voxels, TR/TE = 2500/3.77 ms). For diffusion analyses we acquired two separate single-shot EPI diffusion weighted images with gradients applied along six directions (b = 100 s/mm^2^) and 64 directions (b = 1000 s/mm^2^) respectively. Diffusion imaging parameters were set at 73 contiguous axial slices with 2 mm^3^ voxels and TR/TE = 17,300/81 ms. For skull segmentation, we acquired T2-weighted images with the following parameters: 176 contiguous slices, 1 mm^3^ voxels, TR/TE = 3200/409 ms.

2.6. Total intracranial volume {#s0040}
------------------------------

Total intracranial volume was measured by exporting the inner surface of the skull from FSL version 4.1 Brain Extraction Tool ([@bb0310]). These initial intracranial masks were then manually cleaned by expert raters to fill the enclosure within the inner surface of the skull. The inferior portion of the mask terminated on a straight line between the bottom of the occipital bone and the clivus. Reliability was high (intra-rater and inter-rater reliability DSC \> 0.99). The final variable of interest was total intracranial volume in mm^3^.

2.7. Cortical gray, subcortical gray, white matter segmentation {#s0045}
---------------------------------------------------------------

Cortical reconstruction and volumetric segmentation was performed with the Freesurfer image analysis suite, which is documented and freely available for download online (<http://surfer.nmr.mgh.harvard.edu/>). The technical details of these procedures are described in prior publications ([@bb0090]; [@bb0095]; [@bb0130]; [@bb0135]; [@bb0125]; [@bb0140]; [@bb0145]; [@bb0150]; [@bb0155]; [@bb0295]; [@bb0190]; [@bb0220]). This processing includes removal of non-brain tissue using a hybrid watershed/surface deformation procedure ([@bb0295]), automated Talairach transformation, segmentation of the subcortical white matter and deep gray matter volumetric structures ([@bb0145]; [@bb0150]), intensity normalization ([@bb0305]), tessellation of the gray matter white matter boundary, automated topology correction ([@bb0140]; [@bb0300]), and surface deformation following intensity gradients to optimally place the gray/white and gray/cerebrospinal fluid borders at the location where the greatest shift in intensity defines the transition to the other tissue class ([@bb0090]; [@bb0095]; [@bb0125]). Parcellation of the cerebral cortex into units based on gyral and sulcal structure was also performed ([@bb0155]; [@bb0105]). Freesurfer morphometric procedures have been demonstrated to show good test-retest reliability across scanner manufacturers and across field strengths ([@bb0190]).

2.8. Gray matter volume differences: voxel based morphometry {#s0050}
------------------------------------------------------------

We performed a Voxel Based Morphometry analysis on T1 structural images to investigate voxel-wise gray matter differences between PD patients and control participants. An optimized Voxel Based Morphometry protocol was carried out, using FSL software package version 5.0. First, structural images were reoriented to match the MNI 152 standard space orientation. Brains of the reoriented structural images were extracted using FSL\'s Brain Extraction Tool. Second, brain-extracted images were segmented into gray matter, white matter, and cerebral spinal fluid to create study specific gray matter template. All gray matter images were registered to gray matter ICBM-152 template with non-linear registration and averaged across all participants. The averaged image was flipped along the x-axis to create a left-right symmetric, first pass gray matter template. The native gray matter images were re-registered to this first pass gray matter template using non-linear registration, averaged, and flipped along the x-axis. The mirror images were averaged to create the final study-specific gray matter template. All native gray matter images were non-linearly registered to the study-specific gray matter template and "modulated" by compensating for the contraction or enlargement due to non-linear component of spatial transformation. Modulated gray matter images were spatially smoothed with isotropic Gaussian kernel (sigma = 3 mm). Finally, voxel-wise general linear model analysis was applied on the smoothed images, using permutation-based nonparametric testing with multiple comparison correction across space ([@bb0255]).

From the AAL template ([@bb0365]), we extracted caudate, putamen, insula, and anterior cingulate cortex. Dorsolateral prefrontal cortex was located at Brodmann area 9 and 46 by atlas of Talairach and Toumoux ([@bb0335]). For nucleus accumbens, two 5-mm-radius spheres were generated at MNI coordinates (±10, 10, −8) according to previous publication ([@bb0075]; [@bb0340]; [@bb0005]; [@bb0195]). These regions of interest are schematically visualized in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1The schematic map of regions of interest. Yellow: dorsolateral prefrontal cortex. Red: insula. Green: caudate. Orange: anterior cingulate cortex. Cyan: putamen. Right top: Caudal anterior cingulate cortex. Right bottom: nucleus accumbens. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 1

2.9. White matter integrity: fractional anisotropy and leukoaraiosis {#s0055}
--------------------------------------------------------------------

In order to assess group differences in white matter fractional anisotropy values, we utilized TBSS, a method that provides a robust, voxelwise analysis of diffusion data ([@bb0325]). We calculated fractional anisotropy maps using dtifit after correcting for eddy current distortions with eddy_correct; both tools are part of the FSL (<http://www.fmrib.ox.ac.uk/fsl/>) ([@bb0320]). We created a study-specific fractional anisotropy template by averaging representative fractional anisotropy maps from four individuals registered into MNI152 space and then using ANTS ([@bb0035]) to produce a final template from 60 PD fractional anisotropy maps and 41 non-PD peer fractional anisotropy maps. The fractional anisotropy maps from all participants were then aligned to the template image using an automated method implemented in the TBSS pipeline, which applies a non-linear registration of each fractional anisotropy map to the template. A diffusion MRI template was then generated from the average of the normalized fractional anisotropy maps, non-linearly aligned to the target image.

Voxel-wise statistical analysis of the fractional anisotropy data was carried out using TBSS ([@bb0325]). After alignment of the fractional anisotropy maps to the study specific template, a mean fractional anisotropy skeleton was created; this fractional anisotropy skeleton represents the centers of all tracts common to the group. This skeleton was thresholded at a fractional anisotropy level of \>0.2 and voxel-wise statistics were used with randomize to test for differences in fractional anisotropy between 1) PD with high fatigue and PD with low fatigue and 2) non-PD peers with high fatigue and non-PD peers with low fatigue using a two tailed *t*-test. A statistical threshold of p \< 0.05 was applied after family-wise error correction for multiple comparisons following threshold-free cluster enhancement ([@bb0315]).

2.10. Leukoaraiosis {#s0060}
-------------------

The significance of leukoariosis in PD is debated. Leukoariosis is one marker of small vessel vascular disease that could contribute to processing speed and working memory impairments ([@bb0215] Thus, leukoariosis was measured for both PD and non-PD and examined as a possible vascular covariate to white matter integrity. One reliable rater using a locally developed macro for ImageJ ([@bb0015]; <http://rsbweb.nih.gov/ij/docs/index.html>) measured the leukoariosis for all brains. Rater reliability was established with another expert rater using 15 MRIs representing a wide range of lesion severity that were measured in a blind pseudo-random order on three separate occasions with non-consecutive repeats. Leukoariosis spatial overlap was high in all inter- and intrarater reliability comparisons (Inter-rater range: DCS = 0.84--0.93; Intra-rater range = 0.80--0.83; DSC mean ± s.d. = 0.84 ± 0.12; obtaining a DSC value \>0.7 indicates an excellent agreement between two raters; [@bb0390]).

2.11. Statistical analysis approaches {#s0065}
-------------------------------------

Statistical calculations above were performed using a commercially available software package (SPSS, version 19; SPSS, Inc). Variables were confirmed for normality and statistical assumptions prior to all analyses. Parametric analyses were used to complete demographic analyses and to examine cognitive, mood, fatigue, and region of interest neuroanatomical group differences. Due to violations of normality, Mann-Whitney U tests were used to compare Unified Parkinson\'s disease Rating Scale scores. Linear regression analyzed the contribution of the putamen, caudate, insula, anterior cingulate cortex, dorsolateral prefrontal cortex, and nucleus accumbens on the fatigue severity scale treated as a continuous variable. Whole brain analyses (Voxel Based Morphometry, TBSS) were used to examine group differences between high and low fatigue cohorts and are discussed in references and subsections above. To account for potential differences between high and low fatigue groups, we added covariates to regression models to control for differences in total intracranial volume, BDI, Age, sleep duration and Mini-Mental State Examination.

3. Results {#s0070}
==========

Of 105 people enrolled, 63 individuals with PD and 42 non-PD peers completed the study. Four participants (three PD, one control) could not complete MRI scans (claustrophobia, metal artifact) and were excluded from the current analyses. Final analyses were conducted with 60 PD participants and 41 normal controls, totaling 101 subjects.

3.1. Parkinson\'s disease and non-Parkinson\'s disease peer demographic, general cognitive and motor characteristics {#s0075}
--------------------------------------------------------------------------------------------------------------------

As shown in [Table 1](#t0005){ref-type="table"}, PD and control participants were statistically similar in age, education, ratio of male to female, and health comorbidities (all p values \> .05). *Motor:* Individuals with PD were had predominantly unilateral tremor and low disease severity (70% Hoehn and Yahr ≤ 1.5), and 83% had \<10 years of disease duration (two participants self-reported \>20 years duration but had Hoehn and Yahr of 1 and 1.5). One control participant was taking 40 mg of levodopa-based medication for restless leg syndrome. *General cognition*: Groups were significantly different in general cognition as measured by the Mini-Mental State Examination (p \< .05; [Table 1](#t0005){ref-type="table"}) although PD and non-PD individuals both reported independence in instrumental activities of daily living that involved telephone use, housekeeping, and financial management. All but one PD individual independently managed his/her medications. *Mood:* Relative to the non-PD peers, individuals with PD reported greater more symptoms of depression, apathy, and anxiety as measured by the BDI-II (p \< .00). Mini-Mental State Examination, BDI-II, total intracranial volume, and age were included in the general linear model as additional covariates to remove the effects of these parameters. Findings indicate the PD and non-PD groups are well matched demographically, demonstrating expected higher rates of motor abnormalities, but with slightly lower rates of general cognition as well as increased rates of depression, apathy, and state anxiety in the PD group. [Table 2](#t0010){ref-type="table"} presents data on demographic and disease characteristics of high and low fatigue groups with PD and [Table 3](#t0015){ref-type="table"} presents high and low fatigue demographic and clinical characteristics for non-PD controls. Patients were well-matched with the exception of high fatigue patients having greater depression (BDI-II 11.14 ± 6.0 vs. 6.32 ± 4.4, p = 0.001). High and low fatigue controls did not differ in terms of demographic, mood or cognitive measures.Table 1Demographic and neuropsychological information for participants.Table 1Non-Parkinson\'s disease\
(n = 41)Parkinson\'s disease\
(n = 60)P-valueMale:Female43:734:70.143Age (years)68.29 ± 5.0767.58 ± 5.510.514Education (years)16.80 ± 2.2516.40 ± 2.810.444Sleep Duration7.44 ± 0.74[⁎](#tf0015){ref-type="table-fn"}6.85 ± 1.250.005Levodopa Equivalency0.976 ± 6.25[⁎⁎](#tf0020){ref-type="table-fn"}573.65 ± 341.120.001Unified Parkinson Disease Rating Scale-III[a](#tf0005){ref-type="table-fn"}3.36 ± 3.8218.32 ± 9.73\<0.001Disease duration (years)--5.67 ± 5.83--Mini-Mental State Examination29.22 ± 0.96[⁎⁎⁎](#tf0025){ref-type="table-fn"}28.57 ± 1.310.008BDI II2.98 ± 5.148.73 ± 5.570.000Fatigue Severity Scale3.04 ± 1.323.70 ± 1.390.019Leukoariosis[b](#tf0010){ref-type="table-fn"}4194.45 ± 3768.963856.14 ± 5022.300.716total intracranial volume1655418 ± 1204271688759 ± 1583290.257Leukoariosis[b](#tf0010){ref-type="table-fn"}/total intracranial volume0.0025 ± 0.00230.0023 ± 0.00290.601[^1][^2][^3][^4][^5]Table 2Demographic and neuropsychological information for Parkinson\'s disease High Low Fatigue.Table 2Parkinson\'s disease High\
(n = 29)Parkinson\'s disease Low\
(n = 31)P-valueMale:Female24:519:120.065Age (years)67.00 ± 6.0268.10 ± 5.060.447Education (years)16.10 ± 2.8816.68 ± 2.760.434Sleep Duration6.96 ± 1.096.75 ± 1.410.529Levodopa Equivalency626.63 ± 372.17524.10 ± 307.130.256Unified Parkinson Disease Rating Scale-III[b](#tf0035){ref-type="table-fn"}20.67 ± 10.6316.20 ± 8.470.157Disease duration (years)8.72 ± 5.686.32 ± 4.940.085Mini-Mental State Examination[a](#tf0030){ref-type="table-fn"}28.55 ± 1.1528.58 ± 1.460.933BDI II11.14 ± 5.976.32 ± 4.400.001Fatigue Severity Scale43.64 ± 8.6023.77 ± 6.760.000Leukoariosis2762.56 ± 4004.634949.72 ± 5730.060.098total intracranial volume1710059 ± 158,2701668833 ± 158340.318Leukoariosis/total intracranial volume0.002 ± 0.0020.003 ± 0.0030.072[^6][^7]Table 3Demographic and neuropsychological information for non-Parkinson\'s disease High Low Fatigue.Table 3Non-Parkinson\'s disease High\
(n = 19)Non-Parkinson\'s disease Low\
(n = 22)P-valueMale:Female15:419:30.529Age (years)68.68 ± 5.9768.05 ± 4.280.693Education (years)17.05 ± 2.3016.59 ± 2.240.519Mini-Mental State Examination\*29.00 ± 1.2029.41 ± 0.670.178BDI II4.21 ± 6.972.09 ± 3.370.212Fatigue Severity Scale35.79 ± 11.8419.59 ± 6.080.000Leukoariosis5568.51 ± 4595.593007.770.028total intracranial volume1666888 ± 128,8511645513 ± 1147670.577Leukoariosis/total intracranial volume0.003 ± 0.0030.002 ± 0.0010.035

3.2. Fatigue severity scale and regions of interest analysis for Parkinson\'s disease and controls {#s0080}
--------------------------------------------------------------------------------------------------

Data were analyzed using regression models for regions of interest including bilateral caudate, putamen, insula, anterior cingulate cortex, dorsolateral prefrontal cortex, and nucleus accumbens. These regions of interest are schematically visualized in [Fig. 1](#f0005){ref-type="fig"}.

[Table 4](#t0020){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"} show coefficients between Fatigue Severity Scale and regions of interest volumes. For PD patients, gray matter volumes in striatal regions (caudate and putamen) and in insula were moderately negatively correlated with the Fatigue Severity Scale (p \< 0.05) ([Table 4](#t0020){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}A); while for normal controls, gray matter volumes in anterior cingulate cortex and dorsolateral prefrontal cortex suggested an association with the Fatigue Severity Scale at a trend level (p = 0.13 and p = 0.078 respectively) ([Table 4](#t0020){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}B). When including total intracranial volume, BDI, age, sleep duration, and Mini-Mental State Examination as covariates, only gray matter volumes in caudate and putamen negatively correlated with Fatigue Severity Scale for PD patients; control analyses were unchanged.Table 4The correlation of Fatigue score and regions of interest volume.Table 4Sig. PParkinson\'s diseaseNon-Parkinson\'s diseaseFatigue Severity Scale_totalFatigue Severity Scale\
Controlled total intracranial volume, BDI-II, Age, Mini-Mental State ExaminationFatigue Severity Scale_totalFatigue Severity Scale\
Controlled total intracranial volume, BDI, Age, Mini-Mental State ExaminationCaudate0.004[⁎⁎](#tf0045){ref-type="table-fn"}0.002[⁎⁎](#tf0045){ref-type="table-fn"}0.6650.920Insula0.019[⁎](#tf0040){ref-type="table-fn"}0.0810.5160.392Putamen0.002[⁎⁎](#tf0045){ref-type="table-fn"}0.004[⁎⁎](#tf0045){ref-type="table-fn"}0.5270.534anterior cingulate cortex0.8320.6020.1310.180Caudal anterior cingulate cortex0.8420.4620.3020.405Nucleus accumbens0.3380.9040.9860.659Dorsolateral prefrontal cortex0.9730.7390.0780.052[^8][^9]Fig. 2Scatter plot of correlation between Fatigue Severity Scale and volume of different Regions of Interest. (A) Parkinson\'s disease patients and (B) Non- Parkinson\'s disease peers.Fig. 2

3.3. High vs. low fatigue participants: gray matter differences {#s0085}
---------------------------------------------------------------

PD with high fatigue (Fatigue Severity Scale ≥ 4, 29 subjects) and low fatigue (Fatigue Severity Scale \< 4, 31 subjects) were not statistically different in age, education, sleep duration, or Mini-Mental State Examination. PD with high fatigue had reduced gray matter volume in left caudate relative to PD with low fatigue (p\<0.05 False Discovery Rate corrected; [Table 5A](#t0025){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}A). When relaxing the threshold to uncorrected p \< 0.001, a reduction in gray matter volumes in the bilateral caudate, left calcarine, right putamen, and left angular gyrus was found when comparing the fatigue group to the non-fatigue group ([Fig. 3](#f0015){ref-type="fig"}B and [Table 5B](#t0030){ref-type="table"}).Table 5AAnatomical location of areas of reduced gray matter in Parkinson\'s disease patients with fatigue compared with Parkinson\'s disease patients without fatigue.Table 5A*P*~corrected~Cluster (*k*)MNI coordinatesLocation*xyz*0.01797−161422L Caudate[^10]Fig. 3(A) Areas of reduced gray matter in the analysis of Parkinson\'s disease with high fatigue compared with Parkinson\'s disease with low fatigue in Axial and Coronal slices (controlling for total intracranial volume, BDI, Age, Sleep Duration and Mini-Mental State Examination, False Discovery Rate corrected P \< 0.05). (B) Areas of reduced gray matter in the analysis of Parkinson disease patients (A) and normal controls (B) with fatigue compared with subjects without fatigue (controlling for total intracranial volume, BDI, Age, Sleep Duration, Mini-Mental State Examination, Uncorrected P \< 0.001).Fig. 3Table 5BAnatomical location of areas of reduced gray matter in Parkinson's disease patients with fatigue compared with Parkinson's disease patients without fatigue.Table 5B*P*~uncorrected~Cluster (voxels)MNI coordinatesLocation*xyz*0.000656−14412L Caudate243122216R Caudate170−27−6511L Calcarine 180.0013024−22R Putamen[^11]

Non-PD controls with high fatigue score (Fatigue Severity Scale ≥ 2.89, 19 subjects) and low fatigue score (Fatigue Severity Scale ≤ 2.78, 22 subjects) were not statistically different on any demographics. We found no areas where high fatigue controls had more gray matter atrophy than controls with low fatigue score. However as shown in [Fig. 3](#f0015){ref-type="fig"}C and [Table 5C](#t0035){ref-type="table"}, there were reduced gray matter density in the inferior temporal gyrus and right superior temporal gyrus on the right side when applying uncorrected (p \< 0.001) threshold.Table 5CAnatomical location of areas of reduced gray matter in controls with high fatigue compared with controls with low fatigue.Table 5C*P*~uncorrected~Cluster (voxels)MNI coordinatesLocation*xyz*0.00011154−64−16R Temporal_Inf 3758−146226L Frontal_Sup 10496660R Frontal_Med_Orb 103146012R Frontal_Sup_Medial 10[^12]

3.4. High vs. low fatigue participants: white matter differences {#s0090}
----------------------------------------------------------------

For both PD and non-PD high/low fatigue TBSS analyses there were no areas of significant fractional anisotropy differences. There were no group differences in leukoaraiosis for individuals with PD. In non-PD controls, high fatigue individuals had a greater total volume of leukoariosis than low fatigue individuals (p = 0.035; [Table 3](#t0015){ref-type="table"}).

4. Discussion {#s0095}
=============

Here we report the first study to examine structural correlates of self-reported fatigue in patients with PD and healthy older adults. Using both a priori regions of interest analyses and data-driven approaches we found that PD patients with high fatigue complaints demonstrate atrophy in the dorsal striatum, specifically the caudate. There were no white matter correlates nor any association found with leukoariosis. In contrast, older adults without fatigue experiencing high fatigue demonstrated a higher burden of leukoariosis but had no other specific structural abnormalities. Notably, these findings remained significant even after controlling for total intracranial volume and important potential clinical confounds such as general cognitive function, depression, and sleep that were expectedly more impaired in the PD cohort (but not different between high and low PD patients).

The association of caudate atrophy with fatigue in PD patients is consistent with Chaudhuri and Behan\'s model of basal ganglia dysfunction in central fatigue which hypothesized that dorsal striatal areas and cortical-subcortical networks contribute to perceptions of fatigue due to disruption of internally generated effort ([@bb0060], [@bb0065]). Although the high incidence of fatigue in PD was hypothesized to support this theory, our results provide the first empirical support for this theory in a PD cohort. These data are also consistent with prior lesion-analysis studies in stroke and volumetric studies in multiple sclerosis which similarly show strong associations between self-reported fatigue and caudate damage even when controlling for involvement of other brain areas and clinical factors ([@bb0345]; [@bb0100]).

More recently, several authors have conceptualized fatigue in terms of an ongoing assessment balancing the costs of ongoing activity with the potential awards of that activity ([@bb0055]). There is accumulating evidence that alterations in reward processing may underlie fatigue perception in both healthy and clinical populations ([@bb0055]; [@bb0265]; [@bb0110]). The caudate has been associated with reward motivation in multiple imaging ([@bb0030]) and animal studies ([@bb0380]), and future studies on the mechanisms and phenomenology of fatigue in PD should investigate associations with both effort and reward. The insula is similarly involved in reward processing and was also identified in our volumetric analyses as associated with fatigue in our PD cohort although it did not survive correction for other confounds. Notably, one prior study of PD fatigue utilizing PET scans found reduced ^18^F-dopa uptake in the caudate and insula in high versus low fatigue individuals with PD ([@bb0270]) and the insula is suspected to contrbute to many non-motor symptoms ([@bb0070]). Other brain areas associated with fatigue in PD do not clearly fit in this theoretical framework, namely the angular gyrus and left calcarine cortex. Increased angular gyrus functional connectivity was previously reported in patients with chronic fatigue syndrome, suggesting it may play a role in compensating for fatigue ([@bb0050]). The calcarine cortex has not been shown to be involved in fatigue in other conditions to our knowledge but may relate to possible associations between cognitive dysfunction and fatigue in the PD population which tend to involve visuospatial areas ([@bb0175]).

Older adults without PD did not demonstrate any overlap in terms of brain areas associated with fatigue compared to PD patients suggesting that one or more aspects of PD pathology rather than aging or other non-specific factors is driving fatigue in this cohort. In our non-PD control group a strong correlation was found between fatigue and total leukoariosis. This association may either reflect a central mechanism for fatigue in this population, possibly disruption of cortical subcortical circuits. It is also possible an artifact of an association between cerebrovascular and cardiovascular disease or possibly even a reflection of reverse causation with more fatigued subjects developing cerebrovascular disease due to reduced activity. Similar to our findings in non-PD older adults, atrophy in right-sided temporal regions has also been reported to be associated with fatigue in traumatic brain injury and disruptions in the right arcuate fasciculus have been associated with chronic fatigue syndrome ([@bb0385]; [@bb0285]). This association may due to the role of these right hemisphere structures in attention and arousal ([@bb0245]). As our non-PD group may have had fatigue from a more heterogeneous set of causes it is possible that stronger correlations may have been found in this group if patients were specifically selected for certain traits and/or potential secondary causes of fatigue were excluded.

Limitations of the current study include the absence of objective or subjective measures of sleep quality or daytime sleepiness which could confound reports of fatigue and may underlie some fatigue complaints. We also controlled only for general cognitive function (MMSE). Although there were no differences in other cognitive domains between high and low fatigue in this cohort it is possible we may have detected subtle cognitive differences with a larger cohort that could impact fatigue ([@bb0235]). Although there were no significant differences between groups in levodopa or dopamine agonist use, we did not capture use of all medications (e.g. stimulants, antidepressants) which should be examined in future studies.

5. Conclusions {#s0100}
==============

In conclusion, we found fatigue in PD to be associated with a specific pattern of brain atrophy including the caudate and insula and that this association was not seen in age-matched adults with high fatigue but without PD. These results suggest that PD-related fatigue is a neurobiologically distinct syndrome and that further research is merited to better understand its phenomenology and pathophysiology with the goal of developing better treatments for this common and debilitating symptom.
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[^1]: On medication.

[^2]: Raw voxel volume.

[^3]: Sleep duration = self-report average number of hours of sleep nightly (Non-PD n = 40; PD = 58).

[^4]: Levodopa Equivalency = dosage in non- PD peer due to restless leg syndrome.

[^5]: PD min = 24; max = 30; non-PD min = 25 max = 30.

[^6]: On medication.

[^7]: Raw voxel volume.

[^8]: P \< 0.05.

[^9]: P \< 0.005.

[^10]: A threshold of P \< 0.001 (uncorrected) was used to identify the most significant peaks. Coordinates (*x*, *y*, *z*) refer to standard MNI. Results are listed by cluster size as indicated the number of voxels in a particular cluster. Numbers refer to Brodmann areas (location). L = left; R = right.

[^11]: A threshold of P \< 0.001 (uncorrected) was used to identify the most significant peaks. Coordinates (*x*, *y*, *z*) refer to standard MNI. Results are listed by cluster size as indicated the number of voxels in a particular cluster. Numbers refer to Brodmann areas (location). L = left; R = right.

[^12]: A threshold of P \< 0.001 (uncorrected) was used to identify the most significant peaks. Coordinates (*x*, *y*, *z*) refer to standard MNI. Results are listed by cluster size as indicated the number of voxels in a particular cluster. Numbers refer to Brodmann areas (location). L = left; R = right.
